236 related articles for article (PubMed ID: 21102402)
1. OROS® hydromorphone in chronic pain management: when drug delivery technology matches clinical needs.
Coluzzi F; Mattia C
Minerva Anestesiol; 2010 Dec; 76(12):1072-84. PubMed ID: 21102402
[TBL] [Abstract][Full Text] [Related]
2. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
[TBL] [Abstract][Full Text] [Related]
3. The role of OROS hydromorphone in the management of cancer pain.
Gardner-Nix J; Mercadante S
Pain Pract; 2010; 10(1):72-7. PubMed ID: 19863749
[TBL] [Abstract][Full Text] [Related]
4. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacotherapy of chronic, non-tumour related pain. Efficacy, tolerability and patient benefit of an oral osmotic system with hydromorphone].
Sabatowski R; Giesecke T
MMW Fortschr Med; 2007 Sep; 149 Suppl 3():119-24. PubMed ID: 17955789
[TBL] [Abstract][Full Text] [Related]
6. OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.
Carter NJ; Keating GM
CNS Drugs; 2010 Apr; 24(4):337-61. PubMed ID: 20297858
[TBL] [Abstract][Full Text] [Related]
7. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
Richarz U; Waechter S; Sabatowski R; Szczepanski L; Binsfeld H
Pain Pract; 2013 Jan; 13(1):30-40. PubMed ID: 22510252
[TBL] [Abstract][Full Text] [Related]
8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
9. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of a long-acting OROS hydromorphone formulation.
Turgeon J; Gröning R; Sathyan G; Thipphawong J; Richarz U
Expert Opin Drug Deliv; 2010 Jan; 7(1):137-44. PubMed ID: 19961358
[TBL] [Abstract][Full Text] [Related]
12. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study.
Wallace M; Rauck RL; Moulin D; Thipphawong J; Khanna S; Tudor IC
Int J Clin Pract; 2007 Oct; 61(10):1671-6. PubMed ID: 17877652
[TBL] [Abstract][Full Text] [Related]
13. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
Palangio M; Northfelt DW; Portenoy RK; Brookoff D; Doyle RT; Dornseif BE; Damask MC
J Pain Symptom Manage; 2002 May; 23(5):355-68. PubMed ID: 12007754
[TBL] [Abstract][Full Text] [Related]
14. Oral hydromorphone extended-release.
Guay DR
Consult Pharm; 2010 Dec; 25(12):816-28. PubMed ID: 21172762
[TBL] [Abstract][Full Text] [Related]
15. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
Hale M; Khan A; Kutch M; Li S
Curr Med Res Opin; 2010 Jun; 26(6):1505-18. PubMed ID: 20429852
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the sustained-release hydromorphone in neuropathic pain management: pooled analysis of three open-label studies.
Moulin DE; Richarz U; Wallace M; Jacobs A; Thipphawong J
J Pain Palliat Care Pharmacother; 2010 Sep; 24(3):200-12. PubMed ID: 20718640
[TBL] [Abstract][Full Text] [Related]
17. Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.
Rauck R; Rapoport R; Thipphawong J
Pain Pract; 2013 Jan; 13(1):18-29. PubMed ID: 22537100
[TBL] [Abstract][Full Text] [Related]
18. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
Nalamachu SR; Kutch M; Hale ME
J Pain Symptom Manage; 2012 Dec; 44(6):852-65. PubMed ID: 22795050
[TBL] [Abstract][Full Text] [Related]
19. Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain.
Wallace M; Thipphawong J
Pain Med; 2010 Oct; 11(10):1477-88. PubMed ID: 21199302
[TBL] [Abstract][Full Text] [Related]
20. Dose proportionality and pharmacokinetics of extended-release (OROS®) hydromorphone: a phase 1, open-label, randomized, crossover study in healthy Taiwanese subjects.
Vandenbossche J; Richards HM; Lu CC; Richarz U
Int J Clin Pharmacol Ther; 2014 Mar; 52(3):217-26. PubMed ID: 24472398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
